What is the recommended antibiotic regimen for MRSA infective endocarditis?

• A. Vancomycin + Rifampin, with Gentamicin if susceptible.
• B. Nafcillin plus Gentamicin.
• C. Linezolid monotherapy.
• D. Doxycycline and Cefazolin.

Answer: (A)

Treat MRSA endocarditis with agents that both kill MRSA and address biofilm on any prosthetic material. Vancomycin is the mainstay because it effectively covers MRSA. Rifampin is added when biofilm or prosthetic material is involved because it penetrates biofilms and helps eradicate organisms on prosthetic surfaces; it should never be used alone due to rapid resistance. Gentamicin may be added for synergistic bactericidal effect if the MRSA strain is susceptible, particularly early in therapy, to boost killing, though it requires careful monitoring for kidney toxicity and drug interactions.

Nafcillin targets MSSA, not MRSA, so it isn’t appropriate here. Linezolid can be used in some MRSA infections but as monotherapy it’s less ideal for endocarditis due to slower bactericidal activity and hematologic risks. Doxycycline with cefazolin isn’t effective for MRSA endocarditis because doxycycline has limited bactericidal activity against MRSA and cefazolin isn’t reliable for MRSA.

So the combination of vancomycin with rifampin, adding gentamicin if the organism is susceptible, provides broad MRSA coverage with enhanced activity against biofilm-associated endocarditis.